Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06613841 · ClinicalTrials.gov registry record · Early Phase 1

Multitracer [18F]Fluciclovine and 18F-FDG PET, and Advanced MRI for Metabolic Profiling of Glioblastoma

A Early Phase 1 study of Glioblastoma and Recurrent Glioblastoma, sponsored by Abramson Cancer Center at Penn Medicine.

Recruiting
Registry status
Early Phase 1
Development phase
15
Enrollment target
2
Study locations

NCT06613841 is a Early Phase 1 study of Glioblastoma and Recurrent Glioblastoma that is actively recruiting participants, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 15 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (86% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06613841, a Early Phase 1 study of Glioblastoma and Recurrent Glioblastoma, is actively recruiting participants, sponsored by Abramson Cancer Center at Penn Medicine.

RECRUITING
Registry status
Early Phase 1
Development phase
15 participants
Enrollment target
2
Study locations

Study Summary

* To perform metabolic phenotyping of treatment naïve and recurrent GBM by multitracer \[18F\]Fluciclovine and 18F-FDG PET. * To compare uptake measures of 18F-Fluciclovine and 18F-FDG and MRI quantification of glutamate and lactate levels to tumor tissue laboratory assays (RNA seq and proteomics) of glutamine/glutamate, glucose, and lactate metabolism. * To perform metabolic phenotyping of treatment naïve and recurrent GBM by advanced MRI methods at 7 Tesla

Conditions Studied

Glioblastoma Recurrent Glioblastoma Glioblastoma Multiforme of Brain

Interventions

  • DRUG Fluciclovine F18

Study Locations (2)

Pennsylvania

  • Hospital of the University of Pennsylvania - Philadelphia
  • University of Pennsylvania - Philadelphia

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2025-05-01
Est. Completion 2026-12-31
Phase Early Phase 1

Sponsor

Abramson Cancer Center at Penn Medicine

402 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06613841

The ClinicalTrials.gov registry entry for NCT06613841 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (86% lower). The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Glioblastoma appearing as the primary indexed condition, and to 1 intervention - of which Fluciclovine F18 is the first listed.

NCT06613841 reports 2 study locations spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT06613841 about?

NCT06613841 is a clinical study titled "Multitracer [18F]Fluciclovine and 18F-FDG PET, and Advanced MRI for Metabolic Profiling of Glioblastoma". * To perform metabolic phenotyping of treatment naïve and recurrent GBM by multitracer \[18F\]Fluciclovine and 18F-FDG PET. * To compare uptake measures of 18F-Fluciclovine and 18F-FDG and MRI quantification of glutamate and lactate levels to tumor tissue laboratory assays (RNA seq and proteomics) o...

What is the current status of trial NCT06613841?

This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 15 participants. The study started on 2025-05-01. Estimated completion is 2026-12-31.

What conditions does trial NCT06613841 study?

This clinical trial studies the following conditions: Glioblastoma, Recurrent Glioblastoma, Glioblastoma Multiforme of Brain.

What interventions are being tested in trial NCT06613841?

The interventions under investigation include: Fluciclovine F18 (DRUG).

Who is sponsoring clinical trial NCT06613841?

This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06613841 being conducted?

This trial has 2 study locations across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Glioblastoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Glioblastoma

All registered trials for this condition

Recurrent Glioblastoma

All registered trials for this condition

Pennsylvania

All trials with a study site in Pennsylvania

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.